Document Detail


Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence.
MedLine Citation:
PMID:  23280711     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The identification and surveillance of patients with preneoplastic lesions at high risk of progressing to gastric cancer (GC) represents the most effective way of reducing the burden of GC. The incomplete type of intestinal metaplasia (IM) could be considered as the best candidate for surveillance. However, the usefulness of subtyping of IM has been considered by some authors as limited and inconsistent. A search was carried out to identify all cross-sectional (n=14) and follow-up (n=10) studies that assessed the risk of GC among subjects with different types of IM. Out of the 14 cross-sectional studies, 13 reported that the prevalence of incomplete IM was statistically significantly higher in GC than in other gastric lesions. Out of the ten follow-up studies, six found a statistically significant association between incomplete IM and subsequent GC risk. The relative risks of GC were from 4- to 11-fold higher for the presence of incomplete type in comparison to complete type or in comparison to the absence of incomplete type, among the studies that reported the magnitude of the risk. According to this comprehensive review, most of the scientific evidence supports the utility of subtyping IM as a predictor of GC risk. Recognizing its usefulness by gastroenterologists should encourage pathologists to subtype IM.
Authors:
Carlos A González; José M Sanz-Anquela; Javier P Gisbert; Pelayo Correa
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2013-02-05
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  133     ISSN:  1097-0215     ISO Abbreviation:  Int. J. Cancer     Publication Date:  2013 Sep 
Date Detail:
Created Date:  2013-08-02     Completed Date:  2013-10-23     Revised Date:  2014-09-02    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1023-32     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 UICC.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Biological Markers
Cross-Sectional Studies
Follow-Up Studies
Humans
Intestines / pathology*
Metaplasia
Precancerous Conditions / pathology*
Risk
Stomach Neoplasms / pathology*
Grant Support
ID/Acronym/Agency:
P01 CA028842/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Biological Markers
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Spectroscopically labeled peptaibiotic analogs: the 4-nitrophenylalanine infrared absorption probe i...
Next Document:  Brain region distribution and patterns of bioaccumulative perfluoroalkyl carboxylates and sulfonates...